Goldman says this biotech could become a global cell therapy

The firm initiated coverage of the stock with a buy rating.

Related Keywords

Ziyi Chen , Goldman Sachs , European Union , Johnson , Legend Biotech , Analyst Ziyi Chen , Goldman Sachs Bdc Inc , Environment , Legend Biotech Corp , Stock Markets , Investment Strategy , Johnson Amp , Business News ,